Abstract:Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, the virus has overwhelmed the world's health. Pregnant women as a vulnerable group, the broad implications of SARS-CoV-2 for obstetrical care and perinatal outcomes have raised concern and promoted the rapid development of research. Chinese clinicians and scientists working in obstetrics rapidly reported globally the clinical characteristics, pregnancy outcomes, and vertical transmission potential of SARS-CoV-2 infection in pregnancy on February 12, 2020[1] and published clinical management consensus specific for SARS-CoV-2 infection in pregnancy at the earliest time,[2] which were valuable for preventive and clinical practice in China and elsewhere in the early stages of the pandemic. With the passing of time and updating of information, developments have been achieved in our understanding of obstetric outcomes, vertical transmission, and therapeutics for the treatment and prevention of SARS-CoV-2 infection; furthermore, the progress shed light on the gaps in current knowledge for future work. Maternal and Fetal Outcomes. Although initial reports suggested that pregnant women with SARS-CoV-2 infection were not prone to experience severe disease,[1,3,4] as the pandemic progresses, more recent data indicated that pregnant patients with SARS-CoV-2 infection are at an increased risk for severe illness compared with non-pregnant patients. Data from the US Centers for Disease Control and Prevention, which compared 386,028 non-pregnant women of reproductive age and 23,434 pregnant women all with symptomatic SARS-CoV-2 infection, showed that pregnant patients with SARS-CoV-2 infection were at a three-fold increased risk for both intensive care unit (ICU) admission and invasive ventilation. Additionally, pregnant individuals were at a 2.4-fold increased risk of needing extracorporeal membrane oxygenation (ECMO) and a 70% increased risk of death.[5] A living meta-analysis reported similar results that pregnancy was a risk factor for severe diseases associated with SARS-CoV-2 infection, like ICU admissions, invasive ventilation, and maternal death.[6] Advanced maternal age, high body mass index, and chronic medical conditions (hypertension, pre-existing diabetes, and cardiovascular disease) are the risk factors for increased SARS-CoV-2 infection severity.[6,7] Furthermore, accumulating evidence showed that SARS-CoV-2 infection, especially severe or critical SARS-CoV-2 infection during pregnancy, might be associated with increased risks of adverse pregnancy outcomes. A meta-analysis including 42 studies involving 438,548 pregnant women with comparison data on evaluating disease severity and perinatal outcomes indicated that compared with no SARS-CoV-2 infection in pregnancy, SARS-CoV-2 infection in pregnancy was associated with 33%, 82%, and 2-fold increased risk of preeclampsia (PE), preterm birth (PTB), and stillbirth, respectively. Moreover, compared with mild SARS-CoV-2 infection, severe SARS-CoV-2 infection was strongly associated with PE, PTB, gestational diabetes, and low birth weight; and the odds ratio reached as high as 4.16, 4.29, 1.99, and 1.89, respectively.[8] Subsequently, two studies found similar findings. One of 1219 pregnant patients with SARS-CoV-2 infection showed that compared with asymptomatic patients, severe-critical SARS-CoV-2 infection was associated with 57%, 61%, and 3.5-fold increased risks of cesarean birth, hypertensive disorders of pregnancy, and PTB.[9] One showed that there was a dose-response relationship between the severity of SARS-CoV-2 infection and the risk of PE and PTB. Pregnant patients with severe SARS-CoV-2 infection had a five-fold greater risk of PTB and PE than asymptomatic patients.[10] The increased risk of PTB associated with SARS-CoV-2 infection might be driven largely by medically indicated PTB.[11] The leading indications reported included PE, small for gestational age, and fetal distress.[11] Additionally, obstetricians might opt to deliver the infant to try to save the critically SARS-CoV-2 infected mother.[12] The increased risk of PE was more likely to be associated with placental vascular and inflammatory changes, and systemic inflammation and hypercoagulability were associated with SARS-CoV-2 infection. For example, a recent view indicated that SARS-CoV-2 can cause endothelitis through infecting angiotensin-converting enzyme 2 (ACE2) which is the cellular receptor of SARS-CoV-2 that normally expressed in endothelial cells, leading to activation of thrombin, intravascular inflammation, and damage of endothelial function in multisystemic organs, which could be one mechanism by which that SARS-CoV-2 infection can be causally linked to PE.[13] Additionally, the causes of stillbirth were likely to be associated with SARS-CoV-2 placentitis, which could lead to severe placental damage.[14] Certainly, new data are highly demanded to further demonstrate the pathological mechanism between SARS-CoV-2 infection and the increased risk of adverse obstetric outcomes, thus potentially preventing and decreasing maternal and fetal mortality and morbidity by possibly identifying novel therapeutic interventions. At this time, data are insufficient to suggest an increased risk of congenital malformation associated with SARS-CoV-2 infection in pregnancy. An observational cohort study with 92 pregnancies exposed to SARS-CoV-2 infection and 292 unexposed pregnancies indicated that maternal SARS-CoV-2 infection during the first months of pregnancy was not associated with fetal major congenital malformations.[15] However, a case report study suggested that maternal SARS-CoV-2 infection in weeks 5 and 6 of embryonic development was associated with neonatal severe eye malformation.[16] Evidence indicated that in utero transmission of SARS-CoV-2 is possible based on the detection of SARS-CoV-2 in intrauterine tissue samples, such as amniotic fluid, placenta, and umbilical cord plasma.[17] Besides, placental expression of ACE2 and transmembrane protease serine 2 (TMPRSS2) required for SARS-CoV-2 entering the cells makes the transplacental transmission of SARS-CoV-2 theoretically feasible.[17] However, the rates of intrauterine vertical transmission of SARS-CoV-2 seem to be uncommon.[17] Additionally, the data on the safety of breastfeeding among mothers infected with SARS-CoV-2 are reassuring.[17] To date, the long-term health consequences of maternal SARS-CoV-2 infection for both the mother and offspring remain largely unclear. A 1-year follow-up of 7772 live births of whom 222 births with SARS-CoV-2 exposure in utero suggested that prenatal SARS-CoV-2 infection was associated with an 86% increased risk for offspring neurodevelopmental disorder, even after adjustment for confounders including PTB.[18] So we did a small case-control study from China, which also indicated that infection with SARS-CoV-2 during pregnancy may have an impact on infant neurobehavioral development between 8 months and 10 months.[19] These highlight the importance of conducting well-controlled follow-up studies to clarify the long-term effects of prenatal SARS-CoV-2 exposure on mother and child. Vaccination:Vaccination is considered the best method to reduce maternal and fetal complications of SARS-CoV-2 infection. Recent studies found that most cases of SARS-CoV-2 infection during pregnancy were among unvaccinated individuals and those who were vaccinated experienced less severe illness.[20] Thus, women planning a pregnancy are advised to get vaccinated against SARS-CoV-2. Available data on SARS-CoV-2 vaccines during pregnancy and lactation suggest that they are safe and effective.[21] However, the data are mostly focused on mRNA vaccines, those about the adenoviral vaccine or inactivated influenza virus vaccines are limited. Additionally, several questions associated with the SARS-CoV-2 vaccines are still needed to be illustrated, including optimal gestational timing of SARS-CoV-2 vaccination, extent of neonatal/infant protection with maternal vaccination, and long-term outcomes. At present, the coverage rate of SARS-CoV-2 vaccines among pregnant persons is still at a low level, the main reasons were concerns about limited information about the vaccine safety, and fear of harm to the fetus or infant. But along with more data and knowledge on vaccination in pregnant and lactating women, we believe more effective strategies to reduce vaccine hesitancy in pregnancy could be developed and the total rates of vaccination in women of childbearing age may be improved. Public Health Issues: The emergence of SARS-CoV-2 pandemic arguably represents the greatest threat to global public health in this century and has lasted longer than many of us would have expected. The pandemic not only has a direct impact of viral illness on health outcomes but also has social impacts, such as disruption of healthcare services, which may also have affected the well-being of humans. Pregnancy cannot pause and be terminated during the pandemic that created endless challenges. Studies have shown that the SARS-CoV-2 pandemic and its effects on healthcare systems have had adverse effects on pregnancy outcomes even among pregnant women without SARS-CoV-2 infection.[22] Thus, planning for robust maternity services and high-quality remote care in any emergency response is of great importance. Healthcare providers, scientific researchers, and policy-makers should learn from this pandemic and prioritize safe and accessible maternity care during the pandemic. The effect of SARS-CoV-2 pandemic has also shown a psychological impact on the mental health of pregnant and postpartum women.[23] Pregnant and breastfeeding women are vulnerable populations to mental health disorders. In the context of the pandemic, maternal psychological problems might be further exacerbated by limited social support, social isolation, change in routine associated with SARS-CoV-2 infection, and especially concerns and fears regarding the risk of morbidity and mortality associated with SARS-CoV-2 infection for themselves, their fetus, or their newborn infants. Therefore, attention should be paid to perinatal mental health during pandemic and timely intervention should be carried out to relieve psychological problems and support the health of both mothers and children. Perspective: Though the rapid advance in the field of SARS-CoV-2 infection and pregnancy is admirable, the impact of SARS-CoV-2 on the maternal/fetal unit from a population health level to a basic science level still has a lot of uncharted territories to explore. Furthermore, the continuously emerging variants of the virus with different transmissibility and varying symptoms make diagnosis, treatment, and the development of a vaccine against the virus challenging. Thus, efforts to understand the virus should continue. Funding This work was supported by a grant from the National Key Research and Development Program of China (No. 2021YFC2700700). Conflicts of interest None.

Coronavirus Disease 2019 (COVID-19) Vaccination in Pregnancy

Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis

Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink

Effects of COVID‐19 vaccination during pregnancy on SARS‐CoV‐2 infection and maternal and neonatal outcomes: A systematic review and meta‐analysis

Covid-19 vaccination and pregnancy: a systematic review of maternal and neonatal outcomes

Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants

Coronavirus disease 2019 (COVID-19) pandemic and pregnancy

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

COVID-19 (SARS-CoV-2) Infection in Pregnancy: A Systematic Review

The impact of maternal SARS-CoV-2 infection and COVID-19 vaccination on maternal-fetal outcomes

SARS-CoV-2 Infection and Pregnancy: Clinical Update and Perspective

Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study

COVID-19 Vaccine Acceptance in Pregnant Women

Obstetric Outcomes during COVID-19 Pandemic: Vaccination and Infection in Pregnancy

COVID-19 vaccination before or during pregnancy results in high, sustained maternal neutralizing activity to SARS-CoV-2 wild-type and Delta/Omicron variants of concern, particularly following a booster dose or infection

[Progress in Epidemiological Research of 2019-Ncov Infection and COVID-19 Vaccination in Pregnancy].

Impact of COVID-19 Vaccination on Women During Pregnancy and Breastfeeding

Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination

COVID-19 vaccination in pregnant and lactating diabetic women

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

COVID-19 and Pregnancy